At Alnylam, we believe that making history means advancing groundbreaking science while shaping a healthier, more equitable, and sustainable future for all," said Yvonne Greenstreet, M.D., Chief ...

An Alnylam spokesperson said the company was evaluating its options and may appeal. A BioNTech spokesperson said the filing "confirms Pfizer's and BioNTech's position that we do not infringe any ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based ...

Alnylam Pharmaceuticals (ALNY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

Alnylam concedes its inability to secure a judgment against Moderna’s products after the court’s claim construction. Moderna’s counterclaims and affirmative defenses were dismissed without ...

Oct 2 (Reuters) - Alnylam Pharmaceuticals (ALNY.O), opens new tab admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's (MRNA.O), opens new tab blockbuster COVID ...

Alnylam added that vutrisiran also produced ... ChatGPT owner OpenAI and said it wants to integrate with Google’s Gemini, has also discussed adding generative AI technology developed by startups ...

Getty Images Alnylam Pharmaceuticals announced a Phase-3 study of its treatment for a rare heart condition showed a significant reduction in deaths and recurrent cardiovascular events. The ...

Alnylam Pharmaceuticals said Monday that a drug to treat a rare genetic heart disorder met all its goals in a late-stage clinical trial, raising the prospect that the medicine could generate ...

Alnylam reported mixed fourth-quarter results. The company also announced changes to its Helios-B phase 3 study of vutrisiran in ATTR-CM. Today's sell-off could present a buying opportunity for ...

Alnylam's shares have seen significant growth, up over 140% since September 2019. The company has secured approvals for five RNAi drugs and aims to become a top-tier biotech company by 2025. The ...